Ganirelix Acetate

Names

[ Name ]:
Ganirelix Acetate

[Synonym ]:
56U7906FQW
D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]- ;L-lysyl-L-prolyl-, acetate (1:2)
Ganirelix acetate
UNII:56U7906FQW
N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D- ;alaninamide acetate (1:2)

Biological Activity

[Description]:

Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS)[1].

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> GNRH Receptor

Research Areas >> Metabolic Disease

[Target]

GnRH[1]

[References]

[1]. Gustofson RL, et al. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod. 2006 Nov;21(11):2830-7.

Chemical & Physical Properties

[ Molecular Formula ]:
C₈₄H₁₂₁ClN₁₈O₁₇

[ Molecular Weight ]:
1690.423

[ Exact Mass ]:
1688.884521

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ RIDADR ]:
NONH for all modes of transport

Articles

Androgens influence microvascular dilation in PCOS through ET-A and ET-B receptors.

Am. J. Physiol. Endocrinol. Metab. 305(7) , E818-25, (2013)

Hyperandrogenism and vascular dysfunction often coexist in women with polycystic ovary syndrome (PCOS). We hypothesized that testosterone compromises cutaneous microvascular dilation in women with PCO...

GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial.

Eur. J. Obstet. Gynecol. Reprod. Biol. 166(1) , 43-6, (2013)

To compare the efficacy of the long GnRH agonist and the fixed GnRH antagonist protocols in IVF poor responders.This was a randomized controlled trial performed in the Iakentro IVF centre, Thessalonik...

Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.

Reprod. Biol. Endocrinol. 10 , 69, (2012)

Management of established severe OHSS requires prolonged hospitalization, occasionally in intensive care units, accompanied by multiple ascites punctures, correction of intravascular fluid volume and ...